Skip to main content
. 2017 Nov 8;6(2):197–211. doi: 10.1007/s40120-017-0084-6

Table 3.

Duration of natalizumab exposure

Total (months)
Mean ± SD 6.6 ± 5.5
Median [min, max] 9.5 [0.0, 16.7]
< 6 months, n (%) 49 (46.2)
≥ 6 and < 12 months, n (%) 41 (38.7)
≥ 12 and < 18 months, n (%) 16 (15.1)
≥ 18 and < 24 months, n (%) 0 (0.0)
≥ 24 months, n (%) 0 (0.0)

SD standard deviation